New trial
Phase 1 Study of XB628 Targeting NKG2A and PD-L1 in Advanced Solid Tumors
- Trial ID
- NCT06952010 on ClinicalTrials.gov
- Cancer type
- Solid Tumors
- Location
- 2 Locations
- Published in
- New in Oncology - June 6, 2025
Exelixis is conducting a first-in-human, open-label, dose-escalation trial of XB628—a bispecific antibody that engages NK cells by targeting NKG2A and PD-L1—in patients with recurrent advanced or metastatic solid tumors.
More in multiple solid tumors
-
Trial result · Oct 15, 2026 · NCT04985604
Tovorafenib (type II RAF inhibitor; BRAF/CRAF) drives 43% ORR in BRAF/RAF1-altered R/R solid tumors -
New trial · Oct 15, 2026 · NCT07819136
Phase 1/2 ZINNIA tests REC-7735, a PIK3CA H1047R-selective inhibitor, across advanced solid tumors -
New trial · Oct 15, 2026 · NCT07843550
Phase 1/2 larotrectinib plus pembrolizumab tests TRK inhibition after checkpoint failure in lung adenocarcinoma and melanoma -
New trial · Oct 15, 2026 · NCT07832630
Phase 2 saruparib tests PARP1 inhibition in HRD-signature-positive solid tumors without prior platinum resistance -
New trial · Oct 15, 2026 · NCT07811297
Phase 1b/2a catequentinib tests angiogenesis blockade alone and in combinations across four solid-tumor settings